Tag Archives: Process Analytical Technology

Drug Regulators, EMA (EMEA), Publishes Draft Guidance on Real Time Release Testing (Parametric Release)

Drug Regulators, EMA (EMEA), Publishes Draft Guidance on Real Time Release Testing (Parametric Release).

Full Text Here

Medicinal products must comply with the approved specifications before they are released into the market. Compliance with release specifications can be demonstrated by performing a complete set of tests on the finished product, according to the approved specifications. Under certain conditions, an alternative strategy to routine testing is possible. So far this concept has been only applied to sterility testing of terminally sterilised products (parametric release). Recent guidelines adopted in the ICH context (ICH Q8, Q9 and Q10) have made possible to apply a similar release strategy to tests other then sterility, this approach has been called Real Time Release testing.
This guideline addresses the requirements for application of RTR testing to different kinds of products e.g. chemical and biological products and its scope is to facilitate the introduction of RTR testing. The guideline replaces the previous guideline on parametric release and does not introduce new requirements, so the parametric release part on the previous guideline is retained unchanged.

Click – CMC (manufacturing) Services – Click

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

ida consultants freestrategyconsultation 515x64 Drug Regulators, EMA (EMEA), Publishes Draft Guidance on Real Time Release Testing (Parametric Release)

Free Strategy Consultation - Biotech Pharma Regualtory

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

ida 100programme 515x64 LowRes Drug Regulators, EMA (EMEA), Publishes Draft Guidance on Real Time Release Testing (Parametric Release)

Drug Regulators EMEA publish Draft Guidance on the Use of Near Infrared Spectroscopy

Drug Regulators EMEA publish Draft Guidance on the Use of Near Infrared Spectroscopy

Full text Hear

Near Infrared Spectroscopy (NIRS) has become a well established technique and has been used for several years in the pharmaceutical industry. The technique is useful for the identification and assay of pharmaceutical starting materials, intermediates and finished products, as well as for in-process control and monitoring purposes. NIRS constitutes one of the major methods in Process Analytical Technologies (PAT). This guideline provides guidance on the development, calibration, validation and maintenance of NIRS methods and the data to be submitted to the competent authorities when NIRS is the subject or part of a marketing authorisation application.
This guideline also clarifies and differentiates the data requirements for the marketing authorisation dossier and those for GMP, including change control.

If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com

Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

ida 100programme 515x64 LowRes Drug Regulators EMEA publish Draft Guidance on the Use of Near Infrared Spectroscopy

Turn your Business Into an Investor Magnet

How to Write a Business Plan – Free E-Course

Get the secrets that turns your project into an investment magnet, 100% of our clients raise the finance they need to take their projects to the next stage, we will share these secrets with you. – Sign up for Free

Grow your Expertise for Free

As you know this website is a great resource for keeping up to date with developments and regulations, why not get our FREE monthly regulatory and market round up. You can un-subscribe at any time and we do not share your details with anybody.

First name

E-mail address

This guideline ap
recombinant vaccines for the prevention and treatment of infectious disease, and provides guidance on quality, non-clinical and clinical aspects.
ida consultants freestrategyconsultation 515x64 Drug Regulators EMEA publish Draft Guidance on the Use of Near Infrared Spectroscopy